The Asia-Pacific Antiviral Drugs Market is expected to reach USD 8.24 billion by 2023 from USD 6.12 billion in 2018, growing at a CAGR of 6.12% during the forecast period, 2018-2023. Antiviral Drugs helps in combating viral infections by hampering the replication of viruses and strengthening the immune response to the viral infection. From the past few years resistance is observed among viruses against different antiviral drugs with increasing diversity of viruses. This challenge leads to the evolution of broad spectrum antiviral drugs that specifically attack viruses at specified targets such as DNA Polymerase, NS3 Protease, & Reverse Transcriptase. These drugs are used to prevent or cure different viral infections such as HIV/AIDS, Hepatitis, influenza, and other viral infections. Asia-Pacific is one of the emerging region for Antiviral Drugs.
The growth of Antiviral drugs in Asia-Pacific market is majorly driven by factors such as increased public awareness, rise in healthcare expenditure, introduction of new and innovative products, and increase in viral infection incidences. In addition, increasing diseased population and rising demand for antiviral drugs are further stimulating the antiviral drugs market. The key restraints of the market are high cost involved in drug development and increase in demand for alternative medicines such as naturopathy, homeopathy, and oriental medicines among others. Majority of population, especially in India and China rely on traditional medicines for treating flu like cold, cough and viral fever.
Asia-Pacific Antiviral Drugs Market is segmented on the basis of Application, Target, and End-Users. Based on Application, the market is classified into HIV/AIDS, Hepatitis, Herpes, Influenza, and Others. On the basis of Target, the market is classified into DNA polymerase, NS3 Protease, Reverse transcriptase, and Others. On the basis of End-Users, the market is classified into Hospitals, Research Institutes, and Laboratory Centers. The Asia-Pacific market is geographically segmented into China, India, Japan, South Korea and Australia.
The major companies dominating the Antiviral Drugs Market are Johnson & Johnson (USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA), Merck and Co. Inc (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United Kingdom), Gilead Sciences (USA), and Abbott Laboratories (USA).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 HIV/AIDS
5.1.3 Hepatitis
5.1.4 Herpes
5.1.5 Influenza
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Application
5.1.8 Market Attractiveness Analysis, By Application
5.1.9 Market Share Analysis, By Application
5.2 Target
5.2.1 Introduction
5.2.2 DNA polymerase
5.2.3 NS3 Protease
5.2.4 Reverse transcriptase
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By Target
5.2.7 Market Attractiveness Analysis, By Target
5.2.8 Market Share Analysis, By Target
5.3 End Users
5.3.1 Introduction
5.3.2 Hospitals/Clinics
5.3.3 Research Institutes
5.3.4 Laboratory Centers
5.3.5 Y-o-Y Growth Analysis, By End Users
5.3.6 Market Attractiveness Analysis, By End Users
5.3.7 Market Share Analysis, By End Users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Target
6.1.3.4 By End-Users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Target
6.1.4.4 By End-Users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Target
6.1.5.4 By End-Users
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis International AG
8.3 Roche Holding AG
8.4 Pfizer
8.5 Merck and Co. Inc
8.6 GlaxoSmithKline plc
8.7 AstraZeneca AB
8.8 Gilead Sciences
8.9 Abbott Laboratories
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
